Abstract Background Exercise therapy during cancer treatment reduces symptom burden and improves quality of life (QoL). Polycythemia vera (PV) is a myeloproliferative neoplasia associated with good overall survival (up to decades) but a significant symptom burden, including thromboembolic events and dysesthesias. There are no specific exercise recommendations for patients with PV. Thus, we aimed to […]
How should we define disease modification in MPN?
by David Wallace A disease modifying drug for MPN patients specifically targets disease-initiating stem cells that lead to MPN phenotypes, leading to regression of the disease while improving associated complications. Our guest MPN expert is Dr. Ghaith Abu-Zeinah from Weill Cornell Medicine in NYC. Listen in to learn more.
MPN Self Advocacy and Education: A Chat with David Wallace
PV Reporter and MPN Cancer Connection founder David Wallace is interviewed on “PV Pod: Stories from the Marrow.” In the newly released podcast, we shed light on MPN self-advocacy and education on myeloproliferative neoplasms. Helpful tips from the podcast: “It’s normal to be depressed and angry about the situation. I think seeking help is very […]
Observational Study Reveals Differences between Aquagenic and Non-aquagenic Itching in MPNs
Abstract Background Pruritus is a frequent symptom experienced by patients with myeloproliferative neoplasms (MPN). Aquagenic pruritus (AP) is the most common type. The Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) self-report questionnaires were distributed to MPN patients before consultations. Objectives The aim of this study was to assess clinical incidence (phenotypical evolution and […]
FDA Extends Review Period for GSK’s Momelotinib
Today, GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for momelotinib by an additional three months to allow for the evaluation of newly submitted data. The revised completion date is now set for 16th September 2023. Despite this […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 41
- Next Page »
